Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Lancet Gastroenterol Hepatol
; 3(6): 404-412, 2018 06.
Article
en En
| MEDLINE
| ID: mdl-29606564
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Fármacos Gastrointestinales
/
Colitis Ulcerosa
/
Enfermedad de Crohn
/
Biosimilares Farmacéuticos
/
Infliximab
/
Anticuerpos Monoclonales
Tipo de estudio:
Clinical_trials
/
Guideline
/
Observational_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2018
Tipo del documento:
Article